‘An investigation into the occurrence and removal of pharmaceuticals in Colombian wastewater’
Impacte
Scholar |
Altres documents de l'autoria: Botero-Coy, Ana Maria; Martínez-Pachón, Diana; Boix Sales, Clara; Rincón, Rolando J.; Castillo, Nancy I.; Arias Marín, L.P.; Manrique Losada, L.; Torres-Palma, Ricardo A.; Moncayo-Lasso, Alejandro; Hernandez, Felix
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/33596
comunitat-uji-handle3:10234/33597
comunitat-uji-handle4:
INVESTIGACIONAquest recurs és restringit
https://doi.org/10.1016/j.scitotenv.2018.06.088 |
Metadades
Títol
‘An investigation into the occurrence and removal of pharmaceuticals in Colombian wastewater’Autoria
Data de publicació
2018Editor
ElsevierISSN
0048-9697; 1879-1026Cita bibliogràfica
Botero-Coy, A. M., et al. "An investigation into the occurrence and removal of pharmaceuticals in Colombian wastewater." Science of The Total Environment 642 (2018): 842-853.Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
https://www.sciencedirect.com/science/article/pii/S0048969718321636Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
In this work, the presence of 20 pharmaceuticals in wastewater from Colombia is investigated. Several widely consumed compounds have been detected in wastewater samples from different origins and geographical areas ... [+]
In this work, the presence of 20 pharmaceuticals in wastewater from Colombia is investigated. Several widely consumed compounds have been detected in wastewater samples from different origins and geographical areas in Colombia. The studied pharmaceuticals included antibiotics, analgesics and anti-inflammatories, cholesterol lowering statin drugs, lipid regulators, and anti-depressants. The investigated samples were urban wastewater collected during one whole week before (influent) and after treatment (effluent) in the wastewater treatment plants (WWTPs) of Bogotá and Medellin. Raw wastewater from the Hospital of Tumaco and from the city of Florencia were also collected. Analyses performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed that most of the target analytes were present in all the wastewater samples. The highest concentrations (up to 50 μg/L) corresponded to acetaminophen, but several antibiotics, such as azithromycin, ciprofloxacin and norfloxacin, and antihypertensive drugs, such as losartan and valsartan, were commonly present in influent wastewater (IWW) at levels above 1 μg/L. Moreover, the treatment applied in WWTPs seemed to not efficiently remove the compounds under study, because most pharmaceuticals were also present in effluent wastewater (EWW) at concentrations close to those of the IWW. Special emphasis was made in this work on the quality of data reported, performing a detailed study of quality control (QC) samples. The analytical approach used –direct injection of 5-fold diluted samples without any additional treatment – is simpler and faster than the commonly applied solid phase extraction (SPE). The use of 12 isotope-labelled internal standards ensured the satisfactory correction of matrix effects for the corresponding analytes. For the remaining 8 compounds, no drastic matrix effects were observed, and only four compounds (cloxacillin, doxycycline, losartan, tetracycline) presented QC recoveries near or slightly below 60%, revealing ionization suppression, particularly in the IWW. Data on the occurrence of pharmaceuticals reported in this paper are the basis for current studies that aim to develop efficient systems for the degradation/removal of these compounds from the aquatic environment. [-]
Publicat a
Science of The Total Environment, 2018, vol. 642Proyecto de investigación
The authors acknowledge the financial support from COLCIENCIAS (project codes 111571149790, 111577757323 and 111571149740) and from Universidad de la Amazonia (project code 600.6.519). Authors from UJI acknowledge the support from Generalitat Valenciana, Spain (research group of excellence Prometeo II 2014/023).Drets d'accés
©
2018
Published
by
Elsevier
B.V
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Apareix a les col.leccions
- IUPA_Articles [306]